Philippe Ledru - 19 Jan 2023 Form 4 Insider Report for Aptose Biosciences Inc. (APTOF)

Role: Chief Commercial Officer
Signature: /s/ Fletcher Payne as attorney-in-fact for Philippe Ledru
Issuer symbol: APTOF
Transactions as of: 19 Jan 2023
Net transactions value: $0
Form type: 4
Filing time: 23 Jan 2023, 18:55:50 UTC
Previous filing: 14 Apr 2022
Next filing: 07 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APTO	Common Shares	Award	$0	+100,000	+20000%	$0.000000	100,500	19 Jan 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APTO	Employee Stock Option (Right to Buy)	Award	$0	+200,000		$0.000000	200,000	19 Jan 2023	Common Shares	200,000	$0.6600	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Fifty percent (50%) of the options vest on January 19, 2024; the remaining fifty percent (50%) vest as follows: One-third (1/3) on January 19, 2025; one-third (1/3) on January 19, 2026; and one-third (1/3) on January 19, 2027.